Table 1 Target and achieved blood glucose and mortality outcome time point by trial
| Â | Intervention group | Control group | |||
|---|---|---|---|---|---|
Study | Glucose target (mM) | Mean achieved glucose (mM) | Glucose target (mM) | Mean achieved glucose (mM) | Mortality outcome time point |
Studies included in the more recent systematic review[2] | |||||
Surgical ICU studies | Â | Â | Â | Â | Â |
   Van den Berghe and colleagues [21] | 4.4 to 6.1 | 5.7 | 10.0 to 11.1 | 8.5 | Hospital |
   Grey and Perdrizet [22] | 4.4 to 6.7 | 6.9 | 10.0 to 12.2 | 9.9 | Hospital |
   Bilotta and colleagues (SAH) [23] | 4.4 to 6.7 | 5.0 | < 12.2 | 8.3 | 6-month |
   He and colleagues [24] | 4.4 to 8.3 | 6.7 | 10.0 to 11.1 | 10.0 | Hospital |
   Bilotta and colleagues (TBI) [25] | 4.4 to 6.7 | 5.1 | < 12.2 | 8.2 | 6-month |
Medical ICU studies | Â | Â | Â | Â | Â |
   Bland and colleagues [26] | 4.4 to 6.1 | 5.8 | 10.0 to 11.1 | 9.8 | 28-day |
   Van den Berghe and colleagues [27] | 4.4 to 6.1 | 6.2 | 10.0 to 11.1 | 8.5 | 90-day |
   Walters and colleagues [28] | 5.0 to 8.0 | 6.9 | ≤15.0 | 8.1 | 30-day |
   Oksanen and colleagues [29] | 4.0 to 6.0 | 5.0 | 6.0 to 8.0 | 6.4 | 30-day |
   Bruno and colleagues [30] | 5.0 to 7.2 | 7.4 | < 11.1 | 10.6 | 90-day |
Mixed medical-surgical ICU studies | Â | Â | Â | Â | Â |
   Mitchell and colleagues [8] | 4.4 to 6.1 | 5.4 | 10.0 to 11.1 | 7.9 | Hospital |
   Azevedo and colleagues [9] | 4.4 to 6.7 | 7.4 | < 10.0 | 8.0 | ICU |
   Preiser and colleagues [11] | 4.4 to 6.1 | 6.6 | 7.8 to 10.0 | 8.2 | Hospital |
   Brunkhorst and colleagues [12] | 4.4 to 6.1 | 6.2 | 10.0 to 11.1 | 8.4 | 90-day |
   Iapichino and colleagues [13] | 4.4 to 6.1 | 6.1 | 10.0 to 11.1 | 9.1 | 90-day |
   He and colleagues [14] | 4.4 to 6.1 | 5.1 | 10.0 to 11.1 | 10.6 | ICU |
   Zhang and colleagues [15] | 4.4 to 6.1 | 6.1 | 10.0 to 11.1 | 7.7 | Hospital |
   De La Rosa and colleagues [16] | 4.4 to 6.1 | 6.5 | 10.0 to 11.1 | 8.2 | Hospital |
   Arabi and colleagues [17] | 4.4 to 6.1 | 6.4 | 10.0 to 11.1 | 9.5 | Hospital |
   Mackenzie and colleagues [18] | 4.0 to 6.0 | 7.0 | < 11.0 | 8.4 | Hospital |
   NICE-SUGAR [4] | 4.5 to 6.0 | 6.4 | < 10.0 | 8.0 | 90-day |
   Farah and colleagues [5] | 6.1 to 7.8 | 7.9 | 7.8 to 11.1 | 9.7 | 28-day |
   Yu and colleagues [7] | 4.4 to 6.1 | 5.7 | 10.0 to 11.1 | 11.1 | Hospital |
   McMullin and colleagues [10] | 5.0 to 7.0 | 7.1 | 8.0 to 10.0 | 9.4 | Hospital |
Additional studies included only in the earlier systematic review[1] | |||||
Surgical ICU studies | Â | Â | Â | Â | Â |
   Stecher and colleagues [32] | 4.4 to 6.1 | n/a | 7.8 to 10.0 | n/a | n/a |
   Kia and colleagues [33] | 4.2 to 6.4 | 6.0 | 10.0 to 11.1 | 8.0 | 90-day |
   Chan and colleagues [34] | 4.4 to 6.7 | 7.0 | < 11.1 | 9.3 | Hospital |
Medical ICU studies | Â | Â | Â | Â | Â |
   Fernandez and colleagues [35] | 4.4 to 6.1 | 6.7 | < 8.3 | 11.4 | Hospital |
   Davies and colleagues [36] | 4.0 to 8.0 | 10.3 | < 10.0 | 10.7 | Hospital |
   Gray and colleagues [37] | 4.0 to 7.0 | 6.3 | < 17.0 | 6.8 | 90-day |